Anika Therapeutics Sees Early Returns on Recent Launches

Anika Therapeutics reported 2Q23 orthopedic sales of $42 million, +16% compared to the second quarter of 2022. The company generated $78.1 million in orthopedic sales for the first half of 2023, +12.7% compared to the prior year period.

Outsized growth in its orthobiologics business stemmed primarily from favorable order timing from...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us